Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Siemens Healthcare assay cleared by the FDA

By Drug Discovery Trends Editor | July 18, 2011

The Siemens Healthcare
Diagnostics D-dimer assay for the company’s Stratus CS Acute Care Diagnostic
System has been cleared by the FDA to exclude pulmonary embolism (PE) in
conjunction with a non-high clinical pretest probability (PTP) assessment model
in point-of-care. Currently, this is the only assay available in the U.S. to achieve
this clinical validity for use in the point-of-care setting.

Studies show that elevated
D-dimer levels, which are indicative of reactive fibrinolysis, correlate with a
variety of clinical conditions, including PE. PE results when a blood clot from
another part of the body, such as the arms or legs, breaks loose (embolizes)
and travels through the blood stream to the lungs, where it can block the
pulmonary artery.

The expanded use of the
Stratus CS system D-dimer test to quickly exclude PE helps physicians at the
point-of-care provide a more timely assessment in acute situations. Combining a
sensitivity of 97% and a negative predictive value (NPV) of 98% with the precision
and speed assets of the Stratus CS system allows clinicians to have greater
confidence, translating to better patient management. Further, results are
available in as little as 14 minutes, and testing can be run on the same tube
as other Stratus assays, eliminating the need to collect additional tubes or
split samples.

“Clinicians in acute care are challenged to make timely decisions that can
literally mean the difference between life and death for their patients,” says
David Stein, PhD, CEO, Point of Care Business Unit, Siemens Healthcare
Diagnostics. “Siemens is excited to be the first company to offer a test for PE
exclusion at the point of care to help these physicians obtain the fast,
accurate results that they need to guide critical clinical decision-making.”

Siemens Healthcare Sector, www.siemens.com/healthcare


Filed Under: Drug Discovery

 

Related Articles Read More >

Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE